CDTX vs NDAQ · rev $1.3M vs P/E 41, rev $8.26B
Cidara Therapeutics Inc (CDTX) versus Nasdaq Inc (NDAQ) — a side-by-side from cached financials, not a winner call.
Cidara Therapeutics Inc (CDTX) is a biotechnology company listed on US.
Nasdaq Inc (NDAQ) is a financial data & stock exchanges company listed on US.
Latest reported CDTX revenue for 2024-12-31 was $1.3M. Net income was -$169.8M. Revenue was down 94.5% from 2023-12-31 to 2024-12-31. CDTX currently screens at market cap $6.96B.
Latest reported NDAQ revenue for 2025-12-31 was $8.26B. Net income was $1.79B. Revenue was up 11.6% from 2024-12-31 to 2025-12-31. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
CDTX currently screens at market cap $6.96B. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
Not investment advice. Open the CDTX and NDAQ stock pages for the full models.
Not investment advice.